Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

New York, New York--(Newsfile Corp. - March 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...

ATNX INVESTOR ALERT: ROSEN, A GLOALLY RECOGNIZED LAW FIRM, Encourages Athenex, Inc. Investors with Losses over $100K to Secure Counsel Before Important Deadline - ATNX

Athenex received a CRL from the FDA for its lead asset Oraxol.

Athenex: The CRL Is Devastating

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline – ATNX

LOS ANGELES--(BUSINESS WIRE)-- #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Athenex investors have until May 3, 2021 to file a lead plaintiff motion. If you suffered a loss on your Athenex investments or

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors

NEW YORK, March 6, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the "Class...

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Athenex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - ATNX

SAN DIEGO & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Athenex, Inc. (NASDAQ: ATNX) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between August 7, 2019 and February 26, 2021. Athenex is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation dr

SHAREHOLDER ALERT: Robbins LLP Announces That Athenex, Inc. (ATNX) is Being Sued for Misleading Shareholders

BENSALEM, Pa.--(BUSINESS WIRE)---- $ATNX #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) securities between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Athenex investors have until May 3, 2021 to file a lead plaintiff motion. Investors suffering losses on their Athenex investments are encouraged to contact the Law Offices of Howard G. Smith to discu

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. (ATNX) Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. SO WHAT: If you purchased Athenex securities during the Class Period you may be

ATNX BREAKING NEWS: ROSEN, A LEADING LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline – ATNX

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) from August 7, 2019 through February 26, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the Western District of New York alleges violations of the Securities Exchange Act of 1934.

ATNX INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Athenex, Inc.

NEW YORK, March 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) resulting from allegations that Athenex...

ATNX LOSSES ALERT: Bernstein Liebhard LLP is Investigating Athenex, Inc. For Violations of the Securities Laws

SAN DIEGO--(BUSINESS WIRE)-- #ATNXstock--The suit alleges defendants issued false statements concerning Athenex business and prospects, resulting in its stock trading at inflated prices.

Notice of Lead Plaintiff Deadline for Shareholders in the Athenex, Inc. Class Action Lawsuit

LOS ANGELES--(BUSINESS WIRE)---- $ATNX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Athenex investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $ATNX #ATNX--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Athenex--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Western District of New York on behalf of investors that purchased Athenex, Inc. (NASDAQ: ATNX) common stock between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”). Investors have until May 3, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsui

ATHENEX ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)---- $ATNX #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX) investors concerning the Company's possible violations of federal securities laws. Athenex is a clinical stage biopharmaceutical company. Its main product candidate is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer. On September 1, 2020, the Company announced that the U.S. Food and Drug Administration (“

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex (ATNX) Investors to Securities Fraud Investigation and Encourages Investors with Losses to Contact Its Attorneys

LOS ANGELES--(BUSINESS WIRE)---- $ATNX #investors--The Law Offices of Frank R. Cruz Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors

NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating claims on behalf of investors of Athenex, Inc. (“Athenex” or the “Company”) (NASDAQ: ATNX).

Athenex Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Athenex, Inc.

SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors with Losses to Contact Its Attorneys, ATNX Reports FDA Complete Response Letter

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Athenex, Inc. (NASDAQ: ATNX). Shares are down over 50% after the Company reported Q4 results and received a complete response letter from the FDA regarding its new drug application for oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The FDA expressed the following: C

SHAREHOLDER ALERT: Labaton Sucharow Investigates Claims On Behalf of Investors of Athenex, Inc. (NASDAQ: ATNX)

Athenex, Inc. (ATNX) CEO Johnson Lau on Q4 2020 Results - Earnings Call Transcript

Shares of Athenex Inc. plummeted 54.6% on very active afternoon trading Monday, enough to be the biggest decliner listed on major U.S. exchanges, after the Food and Drug Administration said the biopharmaceutical company's New Drug Application (NDA) for its metastatic breast cancer treatment, oral paclitaxel plus encequidar, is not ready for approval in its present form. Trading volume spiked to 40.1 million shares, compared with the full-day average of about 1.1 million shares.

Athenex stock plunges to pace all decliners after disappointing FDA response to breast cancer treatment NDA

Lixte Biotech

Morphic Holding Inc

Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharma developing oral integrin therapies for treating chronic diseases, reported positive Phase 1 data for its MORF-057, which is being evaluated for inflammatory bowel disease.

Why Morphic, Athenex, Lixte Biotech Are Moving Today

Boston, Massachusetts--(Newsfile Corp. - March 1, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that it is investigating Athenex, Inc. (NASDAQ: ATNX) for potential violations of the federal securities laws. Before the markets opened on March 1, 2021, Athenex announced that the U.S. Food and Drug Administration (FDA) had issued a complete response letter (CRL) for the company's New Drug Application for oral paclitaxel plus encequidar for the treatment...

SHAREHOLDER ALERT: Athenex, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm

Shares of ATNX stock are hurting on Monday after the U.S. FDA said Athenex's breast cancer treatment drug is not ready for approval. The post ATNX Stock Alert: The FDA News That Has Athenex Shares Plunging Monday appeared first on InvestorPlace.

News for Athenex Stock (ATNX)